Is long-term (≥3 months) vs short-term therapy with vitamin K antagonists (VKAs) associated with differences in the incidence of recurrent venous thromboembolism (VTE), major bleeding, and mortality in patients with symptomatic VTE?
Long-term treatment with VKAs is associated with a reduced risk for recurrent VTE and an increased risk for major bleeding compared with short-term treatment in patients with VTE, but is not associated with differences in mortality.
Middeldorp S, Hutten BA. Long-term vs Short-term Therapy With Vitamin K Antagonists for Symptomatic Venous Thromboembolism. JAMA. 2015;314(1):72-73. doi:10.1001/jama.2015.2693